PM8002 is a Bispecific Antibody Targeting PD-L1 and VEGF.
This is a multicenter, single-arm, open-label phase II study to evaluate the efficacy and safety of PM8002 in combination with chemotherapy in the first-line treatment of subjects with inoperable HCC.